What Delta4 does

Delta4 GmbH is a Vienna-based TechBio company founded in 2018 that builds AI-powered computational tools for drug indication expansion. The company's core product is Hyper-C, a proprietary platform that combines systems biology, computational modeling, artificial intelligence, and large-scale data analysis to detect previously unrecognized relationships between drugs with known safety profiles and new therapeutic indications. Hyper-C is operated by a team of computational biologists who interpret AI-generated insights to identify drug repurposing and indication expansion opportunities, targeting complex and rare diseases where traditional de novo drug discovery is slow and expensive.

Delta4 operates a professional services / enterprise engagement model, applying its in-silico models directly to client drug and indication programs. Customers apply to work with Delta4 through its Services and Partnering pages, and the company sells primarily to pharmaceutical and biotech firms across Europe, with a stated global footprint. Named clients and partners include Takeda, Biogen, Calliditas Therapeutics, Gerot Lannach, 4P Pharma, two undisclosed "Top Pharma" firms in Germany and Scandinavia, and Austrian academic institutions Medizinische Universität Innsbruck and Medizinische Universität Wien. Distribution runs through direct enterprise sales, supplemented by a featured profile on Scientist.com, a marketplace used by pharma research buyers.

The company is privately held with 11-50 employees, headquartered in Purkersdorf, Austria, and led by founder and CEO Kurt Herpel. Only one early-stage funding round is recorded (April 2021, amount undisclosed). Strategic positioning is reinforced by recognition from the Austrian Research Promotion Agency (FFG) and active participation in European biotech industry events such as Bio€quity Europe 2026. Delta4 has not disclosed revenue, patents, headcount growth, or formal funding to date, limiting external visibility into its commercial scale.

Name

Delta4

Legal name

Delta4 GmbH

Website

https://delta4.ai

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Delta4 is an Austrian TechBio company whose proprietary Hyper-C AI platform identifies new therapeutic indications for existing drugs with known safety profiles, serving pharmaceutical, biotech, and academic clients across Europe.

Ownership category

akta.pro rank

Product category

AI Drug Discovery & Indication Expansion

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• AI drug discovery
• Computational biology
• Drug repurposing
• Indication expansion
• In-silico modeling

Headquarters

HQ city

Vienna

HQ country

Austria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Drug Discovery Services: Delta4 offers in-silico modeling services to pharmaceutical and biotech clients, applying their Hyper-C AI platform to accelerate drug and indication programs. The company operates on a services/retainer model, inviting prospective clients to 'Apply our in-silico models to accelerate your drug or indication program.' Revenue is derived from service fees charged to pharma clients seeking indication expansion for existing drugs.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Delta4 operates Hyper-C, a proprietary AI-powered computational platform that combines systems biology, computational modeling, and large-scale data analysis to detect undetected relationships between drugs with known safety profiles and identify new therapeutic indications. The company delivers this capability as in-silico drug discovery and indication expansion services to pharmaceutical and biotech clients, applying the platform to accelerate their drug or indication programs.

Product overview

Delta4 is a TechBio company with a single unified core product offering: the Hyper-C platform. This AI-powered computational platform enables pharmaceutical clients to discover new therapeutic uses for existing drugs by analyzing complex biological data and identifying drug-disease relationships. The platform is operated by a team of computational biologists who interpret AI-generated insights to detect drug indication expansion opportunities, helping get new treatment options to market faster, more cost-effectively, and more safely than traditional drug development approaches.

Differentiator

Problem solved

Functional benefit

Brands

• Hyper-C: Proprietary AI-powered platform used by Delta4 to detect undetected relationships between drugs with known safety profiles to identify new therapeutic indications. Operated by computational biologists to produce unique insights and detect drug indication expansion opportunities.

Products and services

• Hyper-C Platform Proprietary AI-powered platform that combines systems biology, computational modeling, artificial intelligence, and large-scale data analysis to detect undetected relationships between drugs with known safety profiles and identify new therapeutic indications. Operated by skilled computational biologists and applied to accelerate pharmaceutical and biotech drug or indication programs.
• In-Silico Drug Discovery & Indication Expansion Services Professional services applying Delta4's Hyper-C platform to pharmaceutical and biotech clients' drug or indication programs, identifying new therapeutic indications for existing drugs with known safety profiles and accelerating drug development.
• Partnering & Co-Development Programs Collaboration programs enabling pharmaceutical, biotech, and academic partners to work with Delta4 on joint research, co-development, or consortia projects leveraging the Hyper-C platform for indication expansion and drug discovery.

Named customers9 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature1 record

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Austrian Research Promotion Agency (FFG)coreStrategic or Co-development PartnerDelta4 was featured by the Austrian Research Promotion Agency (FFG) for their work advancing computational biology. The FFG recognition highlights Delta4's role in connecting expertise, fostering young talent, and leveraging data-driven innovation to improve patient outcomes in Austria's biotech ecosystem.
• Scientist.comcoreStrategic or Co-development PartnerDelta4 is a proud member of Scientist.com, a platform that streamlines transparency and cooperation between researchers and suppliers. The platform provides a collaboration framework to streamline the typically long process of defining terms and conditions for agreements. Delta4's AI-Powered Hyper-C Platform was featured on Scientist.com for uncovering new drug indications for Iguratimod.
• Top Pharma (Germany)minorStrategic or Co-development PartnerTop Pharma (Germany) is listed as one of Delta4's partners and clients, working with Delta4 on drug discovery and indication expansion programs.
• Top Pharma (Scandinavia)minorStrategic or Co-development PartnerTop Pharma (Scandinavia) is listed as one of Delta4's partners and clients, working with Delta4 on drug discovery and indication expansion programs.
• 4P PharmaminorStrategic or Co-development Partner4P Pharma is listed as one of Delta4's partners and clients in the pharmaceutical sector, collaborating on drug indication expansion.
• BiogenminorStrategic or Co-development PartnerBiogen is listed as one of Delta4's partners and clients in the biotech sector, collaborating on drug discovery programs.
• Calliditas TherapeuticsminorStrategic or Co-development PartnerCalliditas Therapeutics is listed as one of Delta4's partners and clients, working with Delta4 on drug discovery and indication expansion.
• Gerot LannachminorStrategic or Co-development PartnerGerot Lannach is listed as one of Delta4's pharmaceutical partners and clients, collaborating on drug indication programs.
• Medizinische Universität InnsbruckminorStrategic or Co-development PartnerMedizinische Universität Innsbruck is listed as one of Delta4's partners, representing an academic collaboration in the Austrian biotech and pharmaceutical research ecosystem.
• Medizinische Universität WienminorStrategic or Co-development PartnerMedizinische Universität Wien is listed as one of Delta4's partners, representing an academic collaboration in computational biology and drug discovery research.
• TakedaminorStrategic or Co-development PartnerTakeda is listed as one of Delta4's pharmaceutical partners and clients, collaborating on drug discovery and indication expansion programs.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• BenevolentAI: BenevolentAI is a London-based AI drug discovery company that uses machine learning on biomedical knowledge graphs to identify new therapeutic indications and drug-disease relationships — directly comparable to Delta4's Hyper-C platform and indication-expansion focus.
• Schrödinger: Schrödinger provides a physics-based computational platform for molecular simulation, drug discovery, and prediction of drug properties; it competes head-to-head with Hyper-C for pharma's in-silico discovery and indication expansion budgets.
• Recursion Pharmaceuticals: Recursion combines high-throughput biology with AI/ML to discover new therapeutics and indications at scale — a directly comparable AI-driven drug discovery platform targeting similar pharma partnerships.
• Exscientia: Exscientia is an AI-driven pharma company using precision design to accelerate small-molecule drug discovery and indication expansion, offering overlapping value proposition and enterprise pharma client base to Delta4.
• Insitro: Insitro combines ML with high-throughput experimental biology to discover therapeutics and predict drug behavior — competing for the same enterprise pharma AI-discovery partnerships as Delta4.
• Atomwise: Atomwise applies deep learning to structure-based drug design and indication prediction, with a heavy pharma partnership focus; directly comparable to Hyper-C's in-silico approach.
• Valo Health: Valo Health uses AI and patient data to accelerate drug discovery and indication expansion across therapeutic areas, overlapping closely with Delta4's platform-driven pharma services model.

Broad incumbents

• Isomorphic Labs: Isomorphic Labs (Alphabet-owned) builds AI-first drug discovery platforms and partners with major pharma like Novartis and Lilly; a well-capitalized broader incumbent operating in the same AI drug discovery space as Delta4.

Emerging players

• Cyclica: Cyclica is a Toronto-based AI drug discovery company applying proteome-wide and polypharmacology approaches to drug repurposing and indication expansion — an emerging player with comparable technology positioning.
• Owkin: Owkin applies AI to biomedical research and clinical data for pharma and biotech clients, with partial overlap to Delta4's AI-driven drug discovery and disease-mechanism analysis capabilities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/delta4ai
• Xx.com/Delta4ai

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Delta4